ReviewThe Lancet. Oncology2024
Production and regulatory issues for theranostics.
Review in The Lancet. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing Value for Money in Theranostic Nuclear Medicine: A Systematic Review.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paper.NPP - digital psychiatry and neuroscience · 2026Article
- PSMA-Targeted Radioligand Therapy Beyond the Post-Taxane Setting: A Review of Evidence Across the Prostate Cancer Spectrum.Cancers · 2026Review
- Adsorption treatment ofAnnals of nuclear medicine · 2026Article
- Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation.Molecular cancer · 2026Review
- Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno‑PET for adaptive cancer care.Discover oncology · 2026Review
- Emerging role of radiopharmaceutical therapy in oncology: advances, challenges, and future directions.JNCI cancer spectrum · 2026Review
- Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases.Frontiers in nutrition · 2026Review
- Clinical Applications of Theranostics.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Future of radiotheranostics.BMJ oncology · 2026Review
- Challenges and Opportunities in Radioligand Therapy.Journal of nuclear medicine technology · 2025Review
- Review
- NeoadjuvantCancers · 2025Review
- Theranostics in nuclear medicine: the era of precision oncology.Medical oncology (Northwood, London, England) · 2025Review
- Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy-Implications for Radiopharmaceutical Repurposing (Beyond Oncology).Pharmaceutics · 2025Review
- Multidisciplinary Perspectives of Clinical Trials in Theranostics.World journal of nuclear medicine · 2025Review
- ARTnet Perspectives and Contributions to Theranostics.World journal of nuclear medicine · 2025Review
- Theranostics Implementation: Opportunities and Challenges.World journal of nuclear medicine · 2025Article
- Global Challenges in the Provision of Theranostic Services the International Atomic Energy Agency (IAEA) Perspective.World journal of nuclear medicine · 2025Article
- Radiotheranostics in Low- and Middle-Income Countries: Challenges, Practice, and Prospects.World journal of nuclear medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Theranostics has become a major area of innovation and progress in cancer care over the last decade. In view of the introduction of approved therapeutics in neuroendocrine tumours and prostate cancer in the last 10 years, the ability to provide access to these treatments has emerged as a key factor in ensuring global benefits from this cancer therapy approach. In this Series paper we explore the issues that affect access to and availability of theranostic radiopharmaceuticals, including supply and regulatory issues that might affect the availability of theranostic treatments for patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.